Efavirenz – Still First-line King?

Bibliography

• Panel on Antiretroviral Guidelines for Adolescents and Adults. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of health and human services. January 29, 2008;1-128. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed May 14, 2008
   Google Scholar
• Bristol-Myers Squib Company. Sustiva® prescribing information. Princeton, NJ. March 2008 [cited 2008 May 14]; Available from: www.sustiva.com
   Google Scholar
• Young SD, Britcher SF, Tran LO, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995;39(12):2602-5
   PubMed Web of Science ®Google Scholar
• Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004;9(1):57-65
   PubMed Web of Science ®Google Scholar
• Veldkamp AI, Harris M, Montaner JS, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001;184(1):37-42
   PubMed Web of Science ®Google Scholar
• Villani P, Regazzi MB, Castelli F, et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 1999;48(5):712-5
   PubMed Web of Science ®Google Scholar
• Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003;47(1):130-7
   PubMed Web of Science ®Google Scholar
• Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004;18(18):2391-400
   PubMed Web of Science ®Google Scholar
• Kappelhoff BS, Crommentuyn KM, de Maat MM, et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004;43(13):845-53
   PubMed Web of Science ®Google Scholar
• Leth FV, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses 2006;22(3):232-9
   PubMed Web of Science ®Google Scholar
• Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15(1):71-5
   PubMed Web of Science ®Google Scholar
• Nunez M, Gonzalez de Requena D, Gallego L, et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001;28(4):399-400
   PubMed Web of Science ®Google Scholar
• Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44(9):2475-84
   PubMed Web of Science ®Google Scholar
• Joly V, Descamps D, Peytavin G, et al. Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother 2004;48(1):172-5
   PubMed Web of Science ®Google Scholar
• Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003;17(1):F1-5
   Web of Science ®Google Scholar
• Loemba H, Brenner B, Parniak MA, et al. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res 2002;56(2):129-42
   PubMed Web of Science ®Google Scholar
• Loemba H, Brenner B, Parniak MA, et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 2002;46(7):2087-94
   PubMed Web of Science ®Google Scholar
• Tozzi V, Zaccarelli M, Narciso P, et al. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis 2004;189(9):1688-95
   PubMed Web of Science ®Google Scholar
• Shulman NS, Bosch RJ, Mellors JW, et al. Genetic correlates of efavirenz hypersusceptibility. AIDS 2004;18(13):1781-5
   PubMed Web of Science ®Google Scholar
• Clark SA, Shulman NS, Bosch RJ, Mellors JW. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS 2006;20(7):981-4
   PubMed Web of Science ®Google Scholar
• von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007;167(16):1782-90
   PubMed Web of Science ®Google Scholar
• Lazzari S, de Felici A, Sobel H, Bertagnolio S. HIV drug resistance surveillance: summary of an April 2003 WHO consultation. AIDS 2004;18(Suppl 3):S49-53
   Google Scholar
• Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004;9(5):695-702
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. J Acquir Immune Defic Syndr 2006;43(3):284-92
   PubMed Web of Science ®Google Scholar
• Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36(5):1011-9
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363(9417):1253-63
   PubMed Web of Science ®Google Scholar
• Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005;143(10):714-21
   PubMed Web of Science ®Google Scholar
• Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005;38(5):560-5
   PubMed Web of Science ®Google Scholar
• Lochet P, Peyriere H, Lotthe A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003;4(1):62-6
   PubMedGoogle Scholar
• Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002;16(2):299-300
   PubMed Web of Science ®Google Scholar
• Chersich MF, Urban MF, Venter FW, et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006;3:11
   PubMedGoogle Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350(18):1850-61
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Best B. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother 2007;8(3):371-82
   PubMed Web of Science ®Google Scholar
• Maggiolo F. Efavirenz. Expert Opin Pharmacother 2007;8(8):1137-45
   PubMed Web of Science ®Google Scholar
• Vrouenraets SM, Wit FW, van Tongeren J, Lange JM. Efavirenz: a review. Expert Opin Pharmacother 2007;8(6):851-71
   PubMed Web of Science ®Google Scholar
• Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001;345(6):398-407
   PubMed Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341(25):1865-73
   PubMed Web of Science ®Google Scholar
• Manfredi R, Calza L, Chiodo F. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. AIDS 2004;18(17):2331-3
   PubMed Web of Science ®Google Scholar
• Waters L, Stebbing J, Jones R, et al. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. J Antimicrob Chemother 2004;54(2):503-7
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection - ACTG 5142. XVI International AIDS Conference; 2006; Toronto, Canada
   Google Scholar
• Haubrich R RS, DiRienzo G, Komarrow L, et al., and the ACTG 5142 Team. Metabolic outcomes of AVTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. 14th conference on retroviruses and opportunistic infections; 2007 February 25-28; Los Angeles, USA
   Google Scholar
• Clumeck N vLJ, Chiliade P, et al. ARTEMIS: efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naive patients. European AIDS conference; 2007 October 24-27; Madrid, Spain
   Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46(2):125-33
   PubMed Web of Science ®Google Scholar
• Saag MS IP, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine/lamivudine), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study. 4th IAS conference on HIV pathogenesis, treatment, and prevention; 2007 July 22 – 25; Sydney, Australia
   Google Scholar
• Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):39-48
   PubMed Web of Science ®Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38
   PubMed Web of Science ®Google Scholar
• Pozniak A, Morales-Ramirez JO, Mohapi L, et al. 48-week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naive patients. 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, CA
   Google Scholar
• Woodfall B, Vingerhoets J, Peeters M, et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in study TMC125-C227 [abstract no. 483]. 8th International congress on drug therapy in HIV infection; 2006 November 12 – 16; Glasgow, Scotland
   Google Scholar